LENZ Therapeutics: High-Risk, High-Reward Buy — Back the Early Commercial Turnaround
LENZ Therapeutics is a pre-commercial eye-care biotech trading at a $286M market cap after a rocky launch quarter and a recent earnings miss. The company’s lead candidate, LNZ100, has strong Phase 3 data and prescription momentum signals (VIZZ scripts), while fundamentals show a stretched cash profile and heavy shorts. This is a speculative, high-r…